Trial Profile
A phase II, single-center, randomized, controlled, observer-blind study with intra-individual comparisons within two parallel groups to assess the efficacy of a topical Aescin formulation in the treatment of allergic contact dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs MAM 06301 (Primary) ; Hydrocortisone
- Indications Allergic contact dermatitis
- Focus Therapeutic Use
- Sponsors Marinomed Biotechnologie
- 10 Sep 2015 New trial record